News | 14 May 2021
Gap between two doses of Covishield extended; No extension for Covaxin
The COVID Working Group has recommended extension of the gap between the first and second doses of Covishield
The COVID Working Group has recommended extension of the gap between the first and second doses of Covishield
Proactively engaging with foreign vaccine manufacturers like Moderna, Pfizer etc., to apply for Emergency Use Authorization in India so that these vaccines can be easily imported and made available in India
The deal is to sell one of the two business undertakings of ZAHL for a lump sum consideration of Rs. 2921 crores on a cash free and debt free basis,
Eris Lifesciences has reported total income of Rs.1220.57 crores during the 12 months period ended March 31, 2021
BBIL had proposed to carry out Phase II/III clinical trial of Covaxin in the age group of 2 to 18 years
The agreement will help ensure wider reach and access to patients in India
It reported total income of Rs.15299.25 crores during the FY ended March 31, 2021
The additional allocation of Tocilizumab will ensure sufficient availability for COVID-19 patients and augment the government’s efforts to fight the pandemic
The INVANZ brand and generic market had U.S. sales of approximately US $205 million MAT for the most recent twelve months ending March 2021 according to IQVIA Health
The Department of Pharma has allocated this drug amongst the states/UTs based on expected supply that will be available from May 10 to May 31, 2021
Favipiravir is close to Remdesivir, Remdesivir is used to treat moderate to severe cases while Favipiravir is used to treat mild to moderate cases
The tablets will be manufactured and marketed under Vivimed’s brand name “Favulous” across India
The rating withdrawal is based on the company’s request and in line with CRISIL Rating’s policy on withdrawal of ratings.
Alembic has reported total income of Rs.83.79 crores during the FY ended March 31, 2021
State governments and UTs have been asked to monitor proper distribution within the state/UT covering government and private hospitals
Jubilant successfully challenged Bracco's patent infringement claims in an Inter Parties Review (IPR) proceeding before the U.S. Patent Office
Baricitinib was issued a restricted emergency use approval by the Central Drugs Standard Control Organization (CDSCO)
Baricitinib is used in combination with remdesivir for the treatment of suspected or laboratory confirmed COVID-19
Baricitinib is an oral medication that was earlier registered in India for the treatment of moderate to severe active rheumatoid arthritis in adult patients.
Glucon-D, Sugar Free, EverYuth Scrub, Peel Off Face Mask and Nycil maintained their leadership positions in-their respective categories as on March 2021.
Subscribe To Our Newsletter & Stay Updated
